Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer

Metastatic triple-negative breast cancer (mTNBC) is the most aggressive breast cancer subtype. Programmed death ligand 1 (PD-L1) on immune cells (IC) using the VENTANA SP142 assay is linked to improved clinical outcome in atezolizumab plus nab—paclitaxel-treated patients with mTNBC in the IMpassion1...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yijin, Vennapusa, Bharathi, Chang, Ching-Wei, Tran, David, Nakamura, Rin, Sumiyoshi, Teiko, Hegde, Priti, Molinero, Luciana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132905/
https://www.ncbi.nlm.nih.gov/pubmed/33030848
http://dx.doi.org/10.1097/PAI.0000000000000857

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132905/
https://www.ncbi.nlm.nih.gov/pubmed/33030848
http://dx.doi.org/10.1097/PAI.0000000000000857

Ejemplares similares